Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$296,610 Mln
Revenue (TTM)
$54,811 Mln
Net Profit (TTM)
$14,056 Mln
ROE
0.3 %
ROCE
17.7 %
P/E Ratio
21.5
P/B Ratio
6.3
Industry P/E
--
EV/EBITDA
14
Div. Yield
3.1 %
Debt to Equity
0.8
Book Value
$23.9
EPS
$7.3
Face value
--
Shares outstanding
1,908,151,679
CFO
$135,202.00 Mln
EBITDA
$185,521.00 Mln
Net Profit
$116,064.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
| 8.7 | -9.8 | 10.9 | 33.5 | 22.2 | 11.8 | 8.7 |
|
BSE Sensex*
| -11.5 | -10.5 | -11.3 | -0.5 | 8.9 | 8.8 | 11.6 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
| 41.7 | -3.6 | 11.3 | 8.1 | -7.4 | -0.3 | 24.8 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
|
149.8 | 296,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 |
| 208.3 | 388,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 351.5 | 197,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 | |
| 59.4 | 120,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 918.1 | 881,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 | |
| 141.3 | 179,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 | |
| 237.3 | 582,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 920.4 | 116,133.4 | 397,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 | |
| 114.5 | 285,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 27.3 | 151,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart... failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Read more
Chief Executive Officer
Dr. Vasant Narasimhan M.D.
Chief Executive Officer
Dr. Vasant Narasimhan M.D.
Headquarters
Basel
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Novartis AG - ADR is $149.81 (NYSE) as of 18-Mar-2026 16:10 EDT. Novartis AG - ADR has given a return of 22.15% in the last 3 years.
The P/E ratio of Novartis AG - ADR is 21.46 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.92
|
5.77
|
|
2024
|
16.33
|
4.43
|
|
2023
|
14.04
|
4.47
|
|
2022
|
28.04
|
3.29
|
|
2021
|
8.20
|
2.91
|
The 52-week high and low of Novartis AG - ADR are Rs 170.46 and Rs 97.72 as of 19-Mar-2026.
Novartis AG - ADR has a market capitalisation of $ 296,610 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Novartis AG - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-5.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.